Meet with... RCT Ventures

Feb 4 2016https://www.eventbrite.com/e/meet-with-rct-ventures-registration-19857427099

Research Corporation Technologies (RCT Ventures) is focused on investing in the most innovative biomedical opportunities through partnerships with talented entrepreneurs, inventors and founders. The firm has assets of more than $200M to advance technology development through venture investment, partnerships and special licensing programs. In addition to stable investment capital, RCT Ventures brings unparalleled experience and expertise across life science investing to enhance the success of each new venture. Some examples of RCT Ventures' exits include Therapeutic Human Polyclonals, acquired by Roche, VasoNova, acquired by Teleflex, and Axiom Technology Partners, developed by RCT Ventures' medical device incubator Option3 and acquired by Teleflex. More information is available at www.rctech.com.

RCT's investment areas include:

  • Medical Devices that offer minimally invasive solutions and change how health care is delivered to patients
  • Therapeutics that provide sustainable improvements in a patient's quality of life
  • Platforms that are used in the discovery, development, or production of therapeutic products
  • Tools that are used in the research or clinical laboratory setting

Following an overview of RCT Ventures' funding opportunities and key areas of interest, don't miss the opportunity to introduce yourself during the networking lunch. And finally, for those companies who applied online and were approved, one-on-one meetings with RCT Ventures will provide a forum to further discuss your company.


Agenda:
10:30am | Registration Opens and Networking
11:00am | Presentation and Q&A
11:45am | Networking Lunch
1:00-5:00pm | One-on-one Meetings*

*Companies must have applied for a one-on-one meeting ahead of time and be approved. The application period ended on January 13th, 2016.


RCT Ventures Participating Representative:
Chad W. Souvignier, Ph.D. | Vice President, RCT Ventures
Chad joined Research Corporation Technologies (RCT) in 2003 and now serves as Vice President. RCT invests in early stage life science companies and technologies. Chad's investment focus includes companies with therapeutic products, biotechnology platforms, applied biotechnology products, and life science tools. Chad has served as the president of Aeson Therapeutics and on the board of directors of Esperance Pharmaceuticals, Jenrin Discovery, and Calosyn Pharma. Chad began his biotech career with Guilford Pharmaceuticals and held roles in business development and international marketing. Chad holds a Ph.D. in materials science and engineering and a MBA from the University of Arizona.
Connect with Chad: Connect on LinkedIn



Fees:
Presentation & Lunch
$25 | General Public
$35 | General Public Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Registration to attend the presentation, Q&A, and lunch will remain open until noon on February 3rd, 2016 (or sold out).

One-on-One Meeting
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period ended on January 13th, 2016. Your application will be reviewed and you will be notified of acceptance by January 28th, 2016. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.


About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, NCI, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCATS, NINDS, Johnson & Johnson Innovation, Poliwogg, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.


Venue:
JLABS
3210 Merryfield Row
San Diego, CA

Share